The BLA submission in December 2026 is the key binary catalyst; the widening net loss and cash burn rate of ~$8.6M per quarter suggest the company will need additional capital before potential approval. Monitor the BLA filing and FDA acceptance, as well as the Adrenyx distribution timeline and any further debt or equity financing.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $49.34entry
- T+1 · 7d ago −5.42%α −5.05% · $46.67
- T+5 · 17h ago −14.37%α −12.68% · $42.25
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The BLA submission for TA-ERT remains on track for December 2026, and the company amended its Avenue loan to increase Tranche 2 availability to $15M and extended the interest-only period. The separation of the CRHX-101 program into Adrenyx Biosciences with a $5M initial note and planned distribution to shareholders is a strategic restructuring, but the widening net loss and cash burn of $24M in the quarter are the dominant financial facts.
Key Financial Metrics
Key Facts
- R&D expenses rose to $18.1M in Q3 2026 from $5.0M in Q3 2025, driven by TA-ERT manufacturing and clinical costs
- Cash and equivalents $87.7M at Sep 30, 2026, down from $96.3M at Jun 30, 2026; cash runway into H2 2027
- BLA submission for TA-ERT remains on track for December 2026 seeking accelerated approval for MPS IIIB
- Avenue Loan Agreement amended to increase Tranche 2 to $15M and extend interest-only period through March 2027
- CRHX-101 program separated into Adrenyx Biosciences subsidiary; $5M initial convertible note issued; planned stock distribution to SPRB shareholders in H1 2027
Financial Impact
Net loss of $24.0M in Q3 2026, cash burn of ~$8.6M from Q2 2026; EPS miss of $-8.51 vs $-5.51 consensus
Risk Factors
- BLA submission for TA-ERT may be delayed or rejected by FDA
- Cash runway only into H2 2027; additional capital likely needed before potential commercial launch
- EPS miss of 54% vs consensus indicates higher-than-expected operating costs
- Separation of CRHX-101 into Adrenyx may not close as planned or may be taxable to shareholders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-452707 |
| Document: sprb-20261109.htm | 0001193125-26-452707 |
| Document: 0001193125-26-452707-index-headers.html | 0001193125-26-452707 |
| Document: 0001193125-26-452707-index.html | 0001193125-26-452707 |
| Document: 0001193125-26-452707.txt | 0001193125-26-452707 |
| 8-K Data (Synthetic) | 0001193125-26-452707 |
Track record
9 reports on SPRB
Filters
- Nov 10, 20267d ago PTAB Trial Neutral 4/10 Entry $46.67 Now $42.25 −9.46% settles Nov 17
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $46.67 Now $42.25 −9.46% settles Nov 17
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $46.67 Now $42.25 −9.46% settles Nov 17
- Nov 9, 20267d ago 8-K Bearish 5/10 Viewing Entry $49.34 to $42.25 Now $42.25 +14.37% ▲ +14.37% +12.68% vs SPY
- Aug 12, 202613w ago 8-K Neutral 6/10 Entry $47.07 to $52.96 Now $42.25 −10.24% ▲ +12.51% +12.96% vs SPY
- May 13, 202626w ago 8-K Mixed 5/10 Entry $57.55 to $48.25 Now $42.25 −26.59% ▼ −16.16% −15.00% vs SPY
- Apr 21, 202629w ago 424B5 Neutral 5/10 Entry $52.36 to $56.34 Now $42.25 −19.31% ▲ +7.60% +7.55% vs SPY
- Apr 20, 202630w ago 424B5 Neutral 5/10 Entry $51.69 to $54.77 Now $42.25 −18.26% ▲ +5.96% +4.87% vs SPY
- Mar 9, 202636w ago 8-K Mixed 6/10 Entry $62.11 to $60.95 Now $42.25 −31.98% ▼ −1.87% −0.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers